Trade name	Active substance (INN)Inn	Date of EU DC	Subject of extension	MAH	Requirement to fulfil Article 8 of Paediatric Regulation Yes/No
PegIntron	Peginterferon alfa-2b	11/11/2009	Extension of indication of the combination therapy peginterferon alfa-2b and ribavirin to include treatment of the paediatric population.	Schering-Plough Europe	Yes
Rebetol	Ribavirin	11/11/2009	Extension of indication of the combination therapy peginterferon alfa-2b and ribavirin to include treatment of the paediatric population.	Schering-Plough Europe	Yes
Orencia	Abatacept	20/01/2010	Extension of indication to include the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor.	Bristol-Myers Squibb Pharma EEIG	Yes
Reyataz	Atazanavir sulphate	05/07/2010	Extension of indication for Reyataz capsules to include the treatment of HIV-infected children and adolescents above the age of 6 in combination with other antiretroviral medicinal products.	Bristol-Myers Squibb Pharma EEIG	No
M-M-RVAXPRO	Measles, mumps and rubella vaccine (live)	06/09/2010	Extension of indication to include administration to healthy children from 9 months of age.	Sanofi Pasteur MSD, SNC	No
Inomax	Nitric oxide	17/03/2011	Extension of indication to include the treatment of pulmonary hypertension peri- and post heart surgery in children.	INO Therapeutics AB	Yes
Humira	Adalimumab	18/03/2011	Extension of indication to include treatment of active polyarticular juvenile idiopathic arthritis in the paediatric population aged from 4 to 12 years.	Abbott Laboratories Ltd.	Yes
Viread	Tenofovir disoproxil fumarate	24/03/2011	Amendment of indication based on the 48-week results of a safety and efficacy study GS-US-104-0321 in treatment-experienced adolescents aged 12 to 18 years old.	Gilead Sciences International Ltd.	Yes

Trade name	Active substance (INN)Inn	Date of EU DC	Subject of extension	MAH	Requirement to fulfil Article 8 of Paediatric Regulation Yes/No
Invega	Paliperidone	08/04/2011	Extension of indication to include treatment of psychotic or manic symptoms of schizoaffective disorder.	Janssen-Cilag International N.V.	Yes
Revatio	Sildenafil	02/05/2011	Extension of indication in paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension.	Pfizer Ltd.	Yes
Kiovig	Human normal immunoglobulin (ivig)	27/07/2011	Extension of indication to include treatment of multifocal motor neuropathy (MMN). Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT) in adults and children.	Baxter AG	Yes
Roactemra	Tocilizumab	01/08/2011	Extension of indication to include treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.	Roche Registration Ltd.	Yes
Synflorix	Pneumococcal polysaccharide conjugate vaccine (adsorbed)	05/08/2011	Extension of indication to increase the upper age limit of infants and children from 2 years to 5 years.	GlaxoSmith Kline Biologicals S.A.	Yes
Enbrel	Etanercept	24/08/2011	Extension of indication to include lower age range for polyarticular juvenile idiopathic arthritis (JIA) "from the age of 4 years" to "from the age of 2 years".	Pfizer Ltd.	Yes
Enbrel	Etanercept	24/08/2011	Extension of indication to include lower age range for paediatric plaque psoriasis from "from the age of 8 years" to "from the age of 6 years".	Pfizer Ltd.	Yes

Trade name	Active substance (INN)Inn	Date of EU DC	Subject of extension	MAH	Requirement to fulfil Article 8 of Paediatric Regulation Yes/No
Levemir	Insulin detemir	24/10/2011	Extension of indication as add-on therapy to liraglutide treatment.	Novo Nordisk A/S	Yes
Levemir	Insulin detemir	24/10/2011	Extension of indication to children aged 2-5 years	Novo Nordisk A/S	Yes
Soliris	Eculizumab	24/11/2011	Extension of indication to include atypical haemolytic uremic syndrome (aHUS). Additional vaccination and antibiotic prophylaxis recommendation have also been added in section 4.2 for treatment of aHUS in adults and children.	Alexion Europe SAS	Yes
Cervarix	Human papilloma virus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)	05/12/2011	Extension of indication to children from 9 years.	GlaxoSmith Kline Biologicals S.A.	Yes

4.3. New route of administration or new pharmaceutical form for paediatric use

- 14 Centrally authorised products had either a new pharmaceutical form (10/14) and/or a new route of administration (1/14) or a new strength (3/14) authorised that has paediatric interest. It should be noted that even though there is an interest for the paediatric population, the addition of a new strength does not fall under the Article 8 of the Paediatric Regulation.

Table 8: List of paediatric relevant line extensions (addition of new route of administration, a new pharmaceutical form or new strengh) for centrally authorised medicinal products

Trade name	Active substance (INN)	Date of EU CD	Subject of line extension	Paediatric interest	Marketing authorisation holder	Requirement to fulfil Article 8 of Paediatric Regulation?
Aerius	desloratadine	23/04/2007	Addition of new pharmaceutical form: orodispersible tablets, 2.5 mg and 5 mg		Merck Sharp & Dohme Ltd.	No
BeneFIX	nonacog alfa	30/07/2007	Addition of new pharmaceutical form: powder and solvent for solution for injection, 250 IU, 500 IU, 1000 IU		Pfizer Ltd.	No
Ferriprox	deferiprone	19/11/2007	Addition of new pharmaceutical form: oral solution 100 mg/ml.	Already authorised in children	Apotex Europe B.V.	No
Rotarix	rotavirus vaccine, live	01/09/2008	Addition of new pharmaceutical form: oral suspension ("liquid formulation").	Already authorised in children	GlaxoSmithKline Biologicals S.A.	No
Temodal	temozolomide	17/02/2009	Addition of new pharmaceutical form: powder for solution for infusion	Paediatric statement clarifies in 4.1 the use of the products in children from 3 years onwards	Schering-Plough Europe	No
Aptivus	tipranavir	23/06/2009	Addition of new pharmaceutical form: oral solution		Boehringer Ingelheim International GmbH	No
Apidra	insulin glulisine	14/01/2010	Addition of new route of administration: intravenous use.	Already authorised	Sanofi-aventis Deutschland GmbH	No
Norvir	ritonavir	25/01/2010	New strength: 100 mg film coated tablet	Already authorised in children	Abbott Laboratories Ltd.	No
INOmax	nitric oxide	18/03/2011	Addition of new strength: 800 ppm	New strengh adopted in parallel of a new indication		Yes

Trade name	Active substance (INN)	Date of EU CD	Subject of line extension	Paediatric interest	Marketing authorisation holder	Requirement to fulfil Article 8 of Paediatric Regulation?
				Pulmonary hypertension associated with heart surgery (II/19) for adults and children (see section 4.2 of the report)		
ReFacto AF	morocto cog alfa	06/05 /2011	To apply for a Addition of new pharmaceutical form 3000 IU.	Product already authorised in children prior to this procedure.		No
ReFacto AF	morocto cog alfa	06/05 /2011	Addition of new pharmaceutical form: 500, 1000 and 2000 IU powder and solvent for solution for injection in pre-filled syringe.	Product already authorised in children prior to this procedure.		No
Myclausen	mycophenolate mofetil	16/09 /2011	Addition of a new pharmaceutical form and strength 250 mg hard capsules (two presentations)	Product already authorised in children. New lower dosage. Strengh not linked to PIP		No
Viramune	nevirapine	16/09 /2011	Addition of new strengths: 50 mg, 100 mg and 400 mg + a new pharmaceutical form: Prolonged-release tablet	For adults + ado and children from > 3 years onwards		Yes
Inovelon	rufinamide	21/11 /2011	New pharmaceutical form: 40 mg/ml, oral suspension.			Yes
Tamiflu	oseltamivir	28/11 /2011	Addition of the new strength: 6 mg/ml, powder for oral suspension	New paediatric. strengtgh so no linked to PIP		No

4.4. Variation to include statement on waiver or deferral in the SmPC

Summary:

- In total, the SmPCs of 59 centrally authorised medicinal products have been updated to include statement on waiver or deferral on the SmPC.
- The SmPCs of 33/59 centrally authorised medicinal products have been updated in section 5.1 to state that a full waiver has been granted.
- The SmPCs of 26/59 centrally authorised medicinal products have been updated to state that there is an ongoing PIP and that the submission of results of paediatric studies has been deferred
- For 10/59 centrally authorised medicinal products, the SmPC was updated after the product had been authorised (variation) and for 49/59, the statement was included in the SmPC at time of Marketing Authorisation.
- The EMA Report to the European Commission (2010) had identified 5 centrally authorised medicinal products, for which the statement on deferral and / or waiver had been inadvertently omitted. Since, the statement could be added in variations for 3 medicines (the marketing authorisation was withdrawn for the 2 other medicines).

Table 9: Variation procedures for centrally authorised medicines in which, inter alia, a statement on a deferral and / or a waiver was added to the SmPC

Invented name	**INN**	**Marketing authorisation holder**	**Full waiver**	**Deferral**	**Marketing Authorisation (MA) / Variation (V)**	**Date of EC Decision**
Exforge and associated names	Amlodipine besylate/ valsartan/ hydrochloro-thiazide	Novartis Europharm Ltd	X		MA	16/10/2009
Onbrez Breezhaler and associated names	Indacaterol maleate	Novartis Europharm Ltd	X		MA	30/11/2009
Orencia	Abatacept	Bristol Myers Squibb Pharma EEIG	X		V	20/01/2010
Elonva	Corifollitropin	N. V. Organon		x	MA	25/01/2010
Silodyx/ Urorec	Silodosin	Recordati Ireland Ltd.	x		MA	29/01/2010
Revolade	Eltrombopag	GlaxoSmithKline Trading Services Ltd		x	MA	11/03/2010
Duocover	Clopidogrel/ acetylsalicylic acid	Bristol-Myers Squibb Pharma EEIG	x		MA	15/03/2010
Duoplavin	Clopidogrel/ acetylsalicylic acid	Sanofi Pharma Bristol-Myers Squibb SNC	x		MA	15/03/2010
Menveo	Meningococcal	Novartis Vaccines		x	MA	15/03/2010

Invented name	INN	Marketing authorisation holder	Full waiver	Deferral	Marketing Authorisation (MA) / Variation (V)	Date of EC Decision
	group a, c, w-135 and y conjugate vaccine	and Diagnostics SRL				
Ristaben	Sitagliptin	Merck Sharp & Dohme Ltd		x	MA	15/03/2010
Ristfor	Sitagliptin / metformin hydrochloride	Merck Sharp & Dohme Ltd	x		MA	15/03/2010
Arzerra	Ofatumumab	Glaxo Group Ltd	x		MA	19/04/2010
Prolia	Denosumab	Amgen Europe B.V.	x		MA	26/05/2010
Votrient	Pazopanib	Glaxo Group Ltd	x		MA	14/06/2010
Daxas	Roflumilast	Nycomed GmbH	x		MA	05/07/2010
Ozurdex	Dexamethasone	Allergan Pharmaceuticals Ireland	X		MA	27/07/2010
Byetta	Exenatide	Eli Lilly Nederland B.		x	V	06/08/2010
Vpriv	Velaglucerase alfa	Shire Pharmaceuticals Ireland Ltd	x	x	MA	26/08/2010
Brinavess	Vernakalant hydrochloride	Merck Sharp & Dohme Ltd.	x		MA	01/09/2010
Sycrest	Asenapine	N.V. Organon		x	MA	01/09/2010
Raspican	Regadenoson	Gilead Sciences International Ltd.		x	MA	06/09/2010
Twynsta	Telmisartan / amlodipine	Boehringer Ingelheim International GmbH	x		MA	07/10/2010
Ruconest	Conestat alfa	Pharming Group N.V.		x	MA	28/10/2010
Sutent	Sunitinib	Pfizer Ltd	x	x	V	29/11/2010
Brilique/ Possia	Ticagrelor	Astra-Zeneca AB	x		MA	03/12/2010
Sprycel	Dasatinib	Bristol Myers Squibb EEIG		x	V	06/12/2010
Invega	Paliperidone	Janssen-Cilag International NV	x		V	13/12/2010
Baraclude	Entecavir	BRISTOL-MYERS SQUIBB PHARMA EEIG		x	V	16/12/2010
Tasigna	Nilotinib	Novartis		X	V	20/12/2010

Invented name	INN	Marketing authorisation holder	Full waiver	Deferral	Marketing Authorisation (MA) / Variation (V)	Date of EC Decision
		Europharm Ltd				
Fluenz	influenza vaccine (live attenuated, nasal)	MedImmune, LLC	X		MA	27/01/2011
Esbriet	pirfenidone	InterMune Europe Ltd	X		MA	28/02/2011
Xiapex	collagenase clostridium histolyticum	Pfizer Limited	X		MA	28/02/2011
Pumarix	pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted)	GlaxoSmithKline Biologicals s.a.		X	MA	04/03/2011
Teysuno	tegafur / gimeracil / oteracil	Taiho Pharma Europe, Limited	X		MA	14/03/2011
Gilenya	fingolimod	Novartis Europharm Limited		X	MA	17/03/2011
Halaven	eribulin	Eisai Europe Ltd	X		MA	17/03/2011
Jevtana	cabazitaxel	Sanofi-aventis	X		MA	17/03/2011
Viread	Tenofovir disoproxil fumarate	Gilead Sciences International Ltd.		x	V	24/03/2011
Trobalt	retigabine		X	X	MA	28/03/2011
Eliquis	apixaban	Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House		X	MA	18/05/2011
Yellox	bromfenac	Croma Pharma GmbH	X		MA	18/05/2011
Cinryze	c1 inhibitor, human	ViroPharma SPRL		X	MA	15/06/2011
Nulojix	belatacept	Bristol-Myers Squibb Pharma EEIG		X	MA	17/06/2011
Benlysta	belimumab	Glaxo Group Limited		X	MA	13/07/2011
Yervoy	ipilimumab	Bristol-Myers Squibb Pharma EEIG	X		MA	13/07/2011
Victrelis	boceprevir	Merck Sharp & Dohme Ltd		X	MA	18/07/2011
Fampyra	fampridine	Biogen Idec	X		MA	20/07/2011

Invented name	INN	Marketing authorisation holder	Full waiver	Deferral	Marketing Authorisation (MA) / Variation (V)	Date of EC Decision
		Limited				
Trajenta	linagliptin	Boehringer Ingelheim International GmbH		X	MA	24/08/2011
Vibativ	telavancin	Astellas Pharma Europe B.V.		X	MA	02/09/2011
Zytiga	abiraterone	Janssen-Cilag International NV	X		MA	05/09/2011
Incivo	telaprevir	Janssen Cilag International NV		X	MA	19/09/2011
Vectibix	Panitumumab	Amgen Europe B.V.	x		V	10/11/2011
Vyndaqel	tafamidis	Pfizer Specialty UK Limited	X		MA	16/11/2011
Edurant	rilpivirine	Janssen-Cilag International NV		X	MA	28/11/2011
Eviplera	emtricitabine / rilpivirine / tenofovir disoproxil	Gilead Sciences International Limited		X	MA	28/11/2011
Dificlir	fidaxomicin	FGK Representative Service GmbH		X	MA	05/12/2011
Ipreziv	azilsartan medoxomil	Takeda Global Research and Development Centre (Europe) Ltd		X	MA	07/12/2011
Mabthera	Rituximab	Roche Registration Ltd.	X		V	14/12/2011
Nevanac	Nepafenac	Alcon Laboratories (UK) Ltd.	X		V	22/12/2011

4.5. Variation to include paediatric dosing information or recommendations (section 4.2 of SmPC)

- In total, the SmPCs of 63 centrally authorised medicinal products have been updated to include or amend paediatric dosing information or recommendations.
- 79 changes to the authorised section 4.2 of SmPCs were adopted to include include or amend paediatric dosing information or recommendations of these 63 centrally authorised medicinal products (several products had more than 1 change to their SmPC affecting the paediatric docing information or recommendations).

Table 10: List of variations that resulted in addition or amendment of paediatric dosage recommendations (no other paediatric relevant change in the SmPC is considered in this table).

Tradename	Inn	CD	Scope of the change	MAH
Fabrazyme	Agalsidase beta	24/01/2007	Based on the evaluation of Specific Obligation 2 (paediatric clinical study AGAL-016-01), the Marketing Authorisation Holder has applied for an update of sections 4.2, 4.8, 5.1 and 5.2 of the Summary of Product Characteristics. Section 3 of the Packa	Genzyme Europe B.V.
Ferriprox	Deferiprone	26/01/2007	Update of the information pertaining to chronic overdose and the risk of neurological disorders (sections 4.2, 4.4, 4.8 and 4.9) following the assessment of the 13th PSUR, and strengthening the wording on neutropenia and agranulocytosis and the monit	Apotex Europe B.V.
Betaferon	Interferon beta-1b	29/03/2007	Update of section 4.2 of the SPC regarding the use of Betaferon in paediatrics, as recommended by the CHMP. The Package Leaflet was amended accordingly. In addition a mistake was corrected in section 5.1 of the SPC. Furthermore, the product informati	Bayer Pharma AG
Emtriva	Emtricitabine	25/04/2007	Update of sections 4.2 and 5.2 of the SmPC to reflect results of a study evaluating the pharmacokinetics and safety of emtricitabine in neonates and young infants over the first 3 months of life, at CHMP request further	Gilead Sciences International Ltd.
Azopt	Brinzolamide	13/06/2007	Update of SmPC to include information on the paediatric data on Azopt. Amendments have been made to sections 4.2, 4.4, 4.8 and 5.1 of the SPC and to the Package Leaflet as appropriate.	Alcon Laboratories (UK) Ltd.
Ceprotin	Protein c	10/08/2007	Update sections 4.2 and 5.1 of the SmPC to include information on dosing in paediatric patients. Section 4.8 of the SmPC was also updated in order to clarify the assignment of related adverse drug reactions. F	Baxter AG

Tradename	Inn	CD	Scope of the change	MAH
Fasturtec	Rasburicase	10/08/ 2007	Update sections 4.2 and 5.1 of the SmPC with paediatric data. The Package Leaflet has also been updated accordingly. The MAH has also taken the opportunity to update the annexes according to the latest QRD template (version 7.2)	Sanofi-aventis
Tritanrix HepB	Diphtheria (d), tetanus (t), pertussis (whole cell) (pw) and hepatitis b (rdna) (hbv) vaccine (adsorbed)	10/08/ 2007	Update section 5.1 of the SmPC to include information about the immune response induced by the 6, 10, 14-week schedule further to the assessment of the renewal. Section 4.2 "Posology	GlaxoSmithKline Biologicals S.A.
NovoSeven	Eptacog alfa (activated)	03/09/ 2007	Update of section 5.2 of the SmPC based on the results from two pharmacokinetic studies. Consequently, the MAH proposed to update section 4.2 of the SPC with regards to dosing information	Novo Nordisk A/S
Lamivudine ViiV	Lamivudine	20/09/ 2007	Update of SmPC To update sections 3, 4.2 and 5.2 of the SPC to replace film coated tablets by scored film coated tablets for use by paediatric patients.	ViiV Healthcare UK Limited
Epivir	Lamivudine	30/10/ 2007	Update sections 3, 4.2 and 5.2 of the SmPC to replace film coated tablets by scored film coated tablets for use by paediatric patients.	ViiV Healthcare UK Limited
Ziagen	Abacavir sulfate	20/11/ 2007	Update sections 3 and 4 of the SmPC to replace film coated tablets by scored film coated tablets for use by paediatric patients.	ViiV Healthcare UK Limited
RotaTeq	Rotavirus vaccine, live, oral	14/12/ 2007	Update of sections 4., 4.4 and 5.1 of the SmPC regarding administration of Rotateq to prematurely born infan	Sanofi Pasteur MSD, SNC
NovoMix	Insulin aspart	18/12/ 2007	Update of sections 4.2, 5.1 and 5.2 of the SmPC to include information about paediatric use.	Novo Nordisk A/S
Prevenar	Pneumococcal saccharide conjugated vaccine,	06/02/ 2008	Update of sections 4.2, 4.4 and 5.1 with immunogenicity and effectiveness data on the 3 dose immunisation schedule.	Wyeth Lederle Vaccines S.A.

Tradename	Inn	CD	Scope of the change	MAH
	adsorbed			
Avastin	Bevacizumab	26/02/2008	Update of SmPC following the fulfilment of follow-up measures: Section 4.2. and Section 5.2 were revised following the results of a PK study in a limited number of paediatric patients.	Roche Registration Ltd.
Optisulin	Insulin glargine	31/03/2008	Update of section 4.2 of the SmPC to add a more flexible dosing scheme, i.e. administration once daily at any time but the same time each day.	Sanofi-aventis Deutschland GmbH
Aldara	Imiquimod	07/07/2008	Update of sections 4.2, 5.1 and 5.2 of the SmPC following evaluation of paediatric studies in the treatment of molluscum contagiosum.	Meda AB
NovoMix	Insulin aspart	28/07/2008	Update of sections 4.2 and 5.1 of the SmPC to include information regarding the transfer from biphasic human insulin to biphasic insulin aspart 30.	Novo Nordisk A/S
Infanrix penta	Diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) vaccine (adsorbed)	13/08/2008	Update of section 4.2 of the SmPC to harmonise the information on booster vaccination with that of Infanrix hexa.	GlaxoSmithKline Biologicals S.A.
Ziagen	Abacavir sulfate	02/09/2008	Update of sections 4.2 and 5.2 of the SmPC relating to administration of crushed tablets with food and liquid.	ViiV Healthcare UK Limited
Epivir	Lamivudine	05/09/2008	Update of sections 4.2 and 5.2 of the SmPC relating to administration of crushed tablets with food and liquid.	ViiV Healthcare UK Limited
Sustiva	Efavirenz	15/09/2008	Update of section 4.2 and 5.2 of the SmPC to incorporate bioequivalence results of the open capsules, further to request of the CHMP made in the context of the evalution	Bristol-Myers Squibb Pharma EEIG

Tradename	Inn	CD	Scope of the change	MAH
			of PSUR 10.	
Combivir	Lamivudine / zidovudine	16/09/ 2008	Update of sections 4.2 and 5.2 of the SmPC relating to administration of crushed tablets with food and liquid.	ViiV Healthcare UK Limited
Infanrix penta	Diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) vaccine (adsorbed)	30/10/ 2008	Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC based on a review of data available from clinical studies or post-marketing surveillance and in line with relevant guidelines.	GlaxoSmithKline Biologicals S.A.
Rapamune	Sirolimus	30/10/ 2008	Update of sections 4. 2, 4.8, 5.1 and 5.2 of the SmPC to include data from completed clinical trials in paediatric patients, as requested by the CHMP in April 2006.	Pfizer Ltd.
Infanrix hexa	Diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type b (hib) conjugate vaccine (adsorbed)	31/10/ 2008	Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC based on a review of data available from clinical studies or post-marketing surveillance and in line with relevant guidelines.	GlaxoSmithKline Biologicals S.A.

Tradename	Inn	CD	Scope of the change	MAH
Telzir	Fosamprenavir	22/12/2008	Update of section 4.2 of the SmPC in order to clarify the dosing recommendations in children further to the CHMP conclusion on a clinical follow-up measure.	ViiV Healthcare UK Limited
BYETTA	Exenatide	07/01/2009	Update of sections 4.2 and 5.2 of the SmPC with information regarding pharmacokinetic data in adolescents from study 2993-124 (PK/PD in adolescents).	Eli Lilly Nederland B.V.
Tamiflu	Oseltamivir	26/01/2009	Update of section 4.2 of the SmPC to provide instructions on the extemporaneous preparation of liquid formulations of Tamiflu using the capsule contents.	Roche Registration Ltd.
Onsenal	Celecoxib	17/03/2009	Alignment of SmPC of Onsenal with SmPC of Celebra (version date 14 November 2007) as requested by the CHMP at the time of the opinion on the 4th Annual Re-assessment, with amendment to the sections 4.2.	Pfizer Ltd.
Telzir	Fosamprenavir	25/03/2009	Update of section 4.2, 4.3, 4.4 and 5.2 of the SmPC.	ViiV Healthcare UK Limited
Alisade	Fluticasone furoate	02/06/2009	Update the sections 4.2, 4.4 and 4.8 of the SmPC with safety information following the assessment of the first PSUR.	Glaxo Group Ltd.
Tracleer	Bosentan	01/07/2009	Update of the SmPC with regard to the posology in paediatric patients in section 4.2 of the SPC, further to the results of clinical studies and a review of the literature and post-marketing experience.	Actelion Registration Ltd.
Rotarix	Rotavirus vaccine, live	21/08/2009	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC regarding safety and immunogenicity of Rotarix when administered to pre-term infants with gestational age of 27 to 36 weeks based on a phase IIIb study.	GlaxoSmithKline Biologicals S.A.
Neulasta	Pegfilgrastim	23/10/2009	Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC to add information for physicians on recommended use in paediatric patients based on a clinical study 990130 and publication.	Amgen Europe B.V.

Tradename	Inn	CD	Scope of the change	MAH
Tamiflu	Oseltamivir	23/10/2009	Update of sections 4.2 of the SmPC to provide instructions to prepare home and pharmacy extemporaneous formulations from Tamiflu 30, 45 and 75mg capsules.	Roche Registration Ltd.
Ketek	Telithromycin	04/11/2009	Update of of sections 4.2 and 5.2 of the SmPC following CHMP request further to the evaluation of paediatric data in accordance with article 46 of the paediatric regulation.	Aventis Pharma S.A.
Exjade	Deferasirox	23/11/2009	Update of Section 4.2 of the SmPC to extend the recommended dose range for maintenance therapy to a maximum of 40 mg/kg/day. Consequently the section 4.4 is amended.	Novartis Europharm Ltd.
Focetria	Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) a/california/7/2009 (h1n1)v like strain (x-181)	27/11/2009	Update of sections 4.2, 4.8 and 5.1 of the SmPC to reflect the currently immunogenicity and safety clinical trial data available in children and adolescents, as requested by the CHMP.	Novartis Vaccines and Diagnostics S.r.l.
Pandemrix	Pandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted) a/california/7/2009 (h1n1)v like strain (x-179a)	27/11/2009	Update of SmPC, Annex II and Package Leaflet To update sections 4.2, 4.4, 4.8 and 5.1 of the SmPC, and Annex IIC to reflect newly available results from clinical study D-PAN-H1N1-009.	GlaxoSmithKline Biologicals S.A.
Pandemrix	Pandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted) a/california/7/2009 (h1n1)v like strain (x-179a)	09/12/2009	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC to reflect new safety and efficacy data post dose 2 (half adult dose) from a study in children aged 6 to 35 months (D-Pan-H1N1-009).	GlaxoSmithKline Biologicals S.A.

Tradename	Inn	CD	Scope of the change	MAH
Pandemrix	Pandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted) a/california/7/ 2009 (h1n1)v like strain (x-179a)	22/12/ 2009	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC to reflect post dose 2 safety and immunogenicity results from a phase III study.	GlaxoSmithKline Biologicals S.A.
Focetria	Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) a/california/7/ 2009 (h1n1)v like strain (x-181)	23/12/ 2009	Update of sections 4.2, 4.8 and 5.1 of the SmPC regarding administration of Focetria to children of 3 to 8 years of age based on results of a study in children as requested by the CHMP. Section 4.8 was also updated.	Novartis Vaccines and Diagnostics S.r.l.
Tamiflu	Oseltamivir	20/01/ 2010	Update of sections 4.2 and 4.4 of the SmPC to add information on the use of Tamiflu in premature infants.	Roche Registration Ltd.
Viracept	Nelfinavir	20/01/ 2010	Update of sections 4.2, 4.5 and 5.2 of the SmPC following the CHMP's assessment of PSUR 13 on 21 August 2008.	Roche Registration Ltd.
Xolair	Omalizumab	25/01/ 2010	Update of section 4.2 of the SmPC to amend the current dosing table to include patients with baseline IgE concentrations of up to 1500 IU/mL.	Novartis Europharm Ltd.
Tamiflu	Oseltamivir	15/03/ 2010	Update of sections 4.2, 4.4, 4.8, 5.1 and 5.3 of the SmPC with information on the prophylaxis of immunocompromised patients and safety information for the seasonal prophylaxis of children from 1 to 12 years of age.	Roche Registration Ltd.
Norvir	Ritonavir	23/03/ 2010	Update of section 4.2 of the SmPC following the annual review of relevant information on ritonavir-boosted protease inhibitors in line with follow-up measure 033.	Abbott Laboratories Ltd.

Tradename	Inn	CD	Scope of the change	MAH
Kaletra	Lopinavir / ritonavir	30/03/ 2010	Update of sections 4.2, 4.5, 4.8 and 5.1 of the SmPC of the Kaletra film-coated tablets (200/50 mg and 100/25 mg) based on the Phase III study M06-80.	Abbott Laboratories Ltd.
Focetria	Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) a/california/7/ 2009 (h1n1)v like strain (x-181)	27/04/ 2010	Update of section 4.2, 4.5, 4.8 and 5.1 of the SmPC to include safety and immunogenicity information following assessment of the H1N1 data available with Focetria in children, adults and the elderly.	Novartis Vaccines and Diagnostics S.r.l.
Mirapexin	Pramipexole	01/07/ 2010	Update of section 5.1 of the SmPC to include results from study 248.644, in line with article 46 of the paediatric legislation. In addition, the description of the paediatric population in section 4.2 and 5.1	Boehringer Ingelheim International GmbH
Celvapan	Pandemic influenza vaccine (h1n1) (whole virion, inactivated, prepared in cell culture)	05/07/ 2010	Update of sections 4.2 and 5.1 of the SmPC based on clinical study results (study 920903) with Celvapan containing 7.5µg H1N1 antigen of the A/H1N1/California/07/2009 influenza virus in infants, children and adolescent aged 6 months to 17 years.	Baxter AG
Cervarix	Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)	06/08/ 2010	Update of section 4.2 with regards to flexibility in dosing schedule of the third vaccination on the basis of results from study HPV-044.	GlaxoSmithKline Biologicals S.A.
Focetria	Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) a/california/7/ 2009 (h1n1)v like strain (x-181)	12/08/ 2010	Update of sections 4.2, 4.8 and 5.1 of the summary of product characteristics regarding administration of Focetria to children of 12 to 35 months of age based on results of study V111_3 in children. Furthermore, posology recommendation in children is	Novartis Vaccines and Diagnostics S.r.l.

Tradename	Inn	CD	Scope of the change	MAH
Abilify	Aripiprazole	05/11/2010	Update of sections 4.2 and 5.1 of the SPC to include information related to studies CN138-178, CN138-179, and CN138-180 conducted in patients (6-17 years) with irritability associated with autistic disorder (IAD) following CHMP conclusions on article	Otsuka Pharmaceutical Europe Ltd.
Twinrix Paediatric	Hepatitis a (inactivated) and hepatitis b(rdna) (hab) vaccine (adsorbed)	05/11/2010	To update section 4.2 "Posology and method of administration" and section 5.1 "Pharmacodynamic properties"of the Twinrix Paediatric SmPC with data coming from two long-term immune persistence studies: HAB-137 and HAB-157 which were conducted in child	GlaxoSmithKline Biologicals S.A.
Ambirix	Hepatitis a (inactivated) and hepatitis b(rdna) (hab) vaccine (adsorbed)	26/11/2010	Update of SPC sections 4.6, 4.7, 4.8 and 4.9 to reflect the safety and reactogenicity data acquired through PMS data. The MAH took also the opportunity to clarify wording in sections 4.1, 4.2, 5.1 and 6.6. The PL is updated accordingly. The MAH furth	GlaxoSmithKline Biologicals S.A.
Aloxi	Palonosetron hydrochloride	20/12/2010	Update of section 4.2, 5.1 and 5.2 of the SmPC to include information from Aloxi paediatric studies PALO-99-07 and PALO-07-29 following P46 procedure. Furthermore, editorial changes have been made in sections 8, 9 and 10 of the SmPC, Annex II and Pac	Helsinn Birex Pharmaceuticals Ltd.
INOmax	Nitric oxide	21/01/2011	Update of sections 4.2, 4.4 and 5.1 of the SmPC to include efficacy and safety data from study INOT27, as requested by the CHMP.	INO Therapeutics AB
Torisel	Temsirolimus	24/01/2011	Update of SmPC sections 4.2, 4.4, 4.8, 5.1 and 5.2 with information based on the results of a Phase I/II safety and exploratory PK study in paediatric subjects with relapsed/refractory solid tumours in line with FUM 007.	Pfizer Ltd.
Protopic	Tacrolimus	21/02/2011	Update of sections 4.4, 4.5 and 5.1 of the SmPC with information related to the impact of the use of tacrolimus ointment on the immunocompetence in paediatric population.	Astellas Pharma Europe B.V.
Erbitux	Cetuximab	18/04/2011	Update of SmPC sections 4.2, 4.4, and 5.2 with information from paediatric PK study.	Merck KGaA

Tradename	Inn	CD	Scope of the change	MAH
Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvant	Pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) a/vietnam/1194/2004 nibrg-14	18/04/2011	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC to reflect new data obtained from study D-Pan H5N1-009, a clinical study is conducted in children aged 3 to 9 years.	GlaxoSmithKline Biologicals S.A.
Prepandrix	Prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted)	20/04/2011	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC to reflect new data obtained from study D-Pan H5N1-009, a clinical study is conducted in children aged 3 to 9 years.	GlaxoSmithKline Biologicals S.A.
Plavix	Clopidogrel	27/05/2011	Update of sections 4.2 and 5.1 of clopidogrel SmPC to include new paediatric information.	Sanofi Pharma Bristol-Myers Squibb SNC
Busilvex	Busulfan	26/07/2011	Update of sections 4.2, 4.4 and 4.5 of the SmPC based on the results of a Phase II study assessed with FU2 007.1 regarding information on seizure prophylaxis treatment.	Pierre Fabre Médicament
Remicade	Infliximab	26/07/2011	Update of sections 2, 4.1, 4.2, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1 and 5.2 of the SmPC to align with the SmPC guideline and the QRD template.	Janssen Biologics B.V.
Faslodex	Fulvestrant	27/07/2011	Update of sections 4.2, 4.4, 5.1 and 5.2 the SmPC based on paediatric data from Study D6992C0044 further to the assessment of the paediatric Article 46 follow up measure (P46 022).	AstraZeneca UK Ltd.
Kiovig	Human normal immunoglobulin (ivig)	27/07/2011	Update of section 4.4 of the SmPC to add a statement regarding hyperproteinemia and hyponatremia. Furthermore, changes are proposed to align the SmPC with the revised Core SmPC for IVIg products.	Baxter AG
Tygacil	Tigecycline	24/08/2011	To update sections 4.2, 4.8 and 5.2 of the Tygacil SmPC with paediatric PK and safety information based on the results of paediatric studies 3074K4-2207-WW and 3074A1-110-US, both submitted and assessed in previous procedures	Pfizer Ltd.

Tradename	Inn	CD	Scope of the change	MAH
Tepadina	Thiotepa	26/08/2011	Update of sections 4.2 and 6.6 of the SmPC regarding reconstitution instructions and final target concentration in the solution for infusion and update of section 6.3 of the SmPC to amend shelf life.	ADIENNE S.r.l.
Removab	Catumaxomab	05/09/2011	Update of section 4.2 of the SmPC to reduce the infusion time from 6 hours to 3 hours following the assessment of PSUR 02, substantiated by new additional data.	Fresenius Biotech GmbH
Viracept	Nelfinavir	05/09/2011	Update of section 4.2 of the SmPC and section 3 of the PL to change the TID dosing recommendations for children aged 3-13 years from 25-30 mg/kg to 25-35 mg/kg and include dose recommendations for tablets for children aged 3-13 years weighing less than 18kg.	Roche Registration Ltd.
ROTARIX	Rotavirus vaccine, live	24/10/2011	To update sections 4.4 and 5.1 of the SmPC to include efficacy data from trial Study Rota-028/029/030 in Asia that was extended up to the age of 3 years.	GlaxoSmithKline Biologicals S.A.
EVOLTRA	Clofarabine	21/11/2011	Update of sections 4.2, 4.4 and 5.2 of the SmPC to include a dosing recommendation for paediatric patients with moderate renal impairment further to the request of the CHMP following the assessment of the responses to Specific Obligation 12 (SO2 012.7).	Genzyme Europe B.V.
FABRAZYME	Agalsidase beta	22/11/2011	Update of Section 4.2 of the SmPC to include a statement about the possibility for the patients to be treated by home infusion with Fabrazyme.	Genzyme Europe B.V.
REYATAZ	Atazanavir sulphate	22/11/2011	Update of sections 4.2, 4.6 and 5.2 of the SmPC with pharmacokinetic and safety data from study AI424182 of ATV/RTV administered as part of HAART to HIV infected pregnant women. The PL was updated accordingly.	Bristol-Myers Squibb Pharma EEIG
SYNAGIS	Palivizumab	19/12/2011	Update of sections 4.4 and 4.8 of the SmPC in order to add a warning for anaphylactic shock.	Abbott Laboratories Ltd.